Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3099% above fair value
$144.67−3.69 (-2.49%)
Close on Nov 3, 2026Market cap $356.93BP/E 149.1Yield 2.27%
Merck Bravecto — Full-year sales by Year
Bravecto — Full-year sales ($B, as reported in Form 10-K)
Merck Bravecto — Full-year sales: $1.10B in FY2025, unchanged from a year earlier.
Latest, FY2025
1.10
Period ended Dec 31, 2025
Change on a year earlier
0.0%
1.10 in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below
Where the FY2025 figure comes from
“Sales of the Bravecto line of products were $1.1 billion in 2025, an increase of 1% compared with 2024.”
Source: Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
Reported in Form 10-K Animal Health MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Bravecto — Full-year sales ($B, as reported in Form 10-K) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.10 | 0.0% | Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 1.10 | 0.0% | Form 10-K (mrk-20241231.htm, filed 2025-02-25) ↗ |
| FY2023 | Dec 31, 2023 | 1.10 | +10.0% | Form 10-K (mrk-20231231.htm, filed 2024-02-26) ↗ |
| FY2022 | Dec 31, 2022 | 1.00 | – | Form 10-K (mrk-20221231.htm, filed 2023-02-24) ↗ |
Cite this data
StockData. (2026). Merck Bravecto — Full-year sales, annual FY2022–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-bravecto-fy-b
See every metric in the Merck KPI table. Data updated Oct 26, 2026.
See a number that looks wrong?